Endurance Wealth Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Endurance Wealth Management’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$20K	Hold	5,700	–	–	﹤0.01%	428
2023 Q1	$12K	Sell	5,700 -1,000	-15%	-$3.18K	﹤0.01%	486
2022 Q4	$81K	Hold	6,700	–	–	0.01%	275
2022 Q3	$43K	Hold	6,700	–	–	0.01%	341
2022 Q2	$31K	Hold	6,700	–	–	﹤0.01%	374
2022 Q1	$58K	Hold	6,700	–	–	0.01%	335
2021 Q4	$96K	Buy	6,700 +100	+2%	+$2.09K	0.01%	294
2021 Q3	$145K	Buy	6,600 +100	+2%	+$1.7K	0.02%	243
2021 Q2	$86K	Buy	6,500 +500	+8%	+$5.72K	0.01%	303
2021 Q1	$61K	Buy	6,000 +5,000	+500%	+$41K	0.01%	337
2020 Q4	$4K	Buy	+1,000	New	+$3.25K	﹤0.01%	541

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Endurance Wealth Management's ORMP Position: Q2 2023 in Review

Endurance Wealth Management held its Oramed Pharmaceuticals (ORMP) position steady in Q2 2023 at 5,700 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #428.

Endurance Wealth Management first reported a position in ORMP in Q4 2020 and has held it in 11 quarters since. The position peaked at $145K in Q3 2021. 50 funds tracked by Wall St. Rank hold ORMP as of Q2 2023.

Endurance Wealth Management held 5,700 shares of Oramed Pharmaceuticals worth $20K as of Q2 2023.
Endurance Wealth Management left its Oramed Pharmaceuticals share count unchanged in Q2 2023.
Oramed Pharmaceuticals made up ﹤0.01% of Endurance Wealth Management's portfolio in Q2 2023, its #428 holding.
Endurance Wealth Management first reported a position in Oramed Pharmaceuticals in Q4 2020 and has held it in 11 quarters since.
Endurance Wealth Management's Oramed Pharmaceuticals position peaked at $145K in Q3 2021.
50 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2023.

Based on Endurance Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.